Novel drug lengthens survival in men with refractory prostate cancer

Share this content:
The pivotal phase III trial involved 755 patients with metastatic prostate cancer that had progressed after treatment with a docetaxel-based regimen and hormone therapy. Participants were randomly assigned to receive either cabazitaxel or mitoxantrone during 10 cycles of chemotherapy with prednisone.

Researchers reported that the odds of overall survival were 30% better with cabazitaxel than with mitoxantone. Median survival rose from 12.7 months with mitoxantron to 15.1 months with cabazitaxel.

According to the press release announcing the study, cabazitaxel is a new type of taxane chemotherapy chemically modified to overcome the resistance mechanism that eventually hampers other taxanes.

“The benefit shown in the trial is clearly in the range of FDA acceptability,” noted A. Oliver Sarton, MD, of Tulane Cancer Center in New Orleans. “This success in refractory prostate cancer is likely to quickly lead to trials in other tumor types.”

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs